Amryt Pharma

Amryt Pharma’s strategy is to build, develop and commercialise a portfolio of medicines focussed on rare and orphan diseases. The initial focus will be on progressing a phase III clinical trial of Episalvan® with a view to achieving approval for treatment of Epidermolysis Bullosa (EB) in both the US and Europe, the risk for which has been reduced by its approval in Partial Thickness Wounds in January 2016.